REFERENCES
1. Xie Y, Su N, Yang J, et al. FGF/FGFR signaling in health and disease. Signal Transduct Target Ther. 2020;5:181.
2. Chen G, Chen L, Li X, Mohammadi M. FGF-based drug discovery: advances and challenges. Nat Rev Drug Discov. 2025;24:335-57.
3. Itoh N, Ohta H, Konishi M. Endocrine FGFs: evolution, physiology, pathophysiology, and pharmacotherapy. Front Endocrinol. 2015;6:154.
4. Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev. 2014;34:280-300.
5. Li HZ, Zhang JL, Yuan DL, et al. Role of signaling pathways in age-related orthopedic diseases: focus on the fibroblast growth factor family. Mil Med Res. 2024;11:40.
6. Giacomini A, Grillo E, Rezzola S, et al. The FGF/FGFR system in the physiopathology of the prostate gland. Physiol Rev. 2021;101:569-610.
7. Yang L, Zhou F, Zheng D, et al. FGF/FGFR signaling: from lung development to respiratory diseases. Cytokine Growth Factor Rev. 2021;62:94-104.
8. Ursic-Bedoya J, Desandré G, Chavey C, et al. FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis. EMBO Mol Med. 2024;16:238-50.
9. Beenken A, Mohammadi M. The structural biology of the FGF19 subfamily. Adv Exp Med Biol. 2012;728:1-24.
10. Bhat N, Esteghamat F, Chaube BK, et al. TCF7L2 transcriptionally regulates Fgf15 to maintain bile acid and lipid homeostasis through gut-liver crosstalk. FASEB J. 2022;36:e22185.
11. Katafuchi T, Makishima M. Molecular basis of bile acid-FXR-FGF15/19 signaling axis. Int J Mol Sci. 2022;23:6046.
12. Wright TJ, Ladher R, McWhirter J, Murre C, Schoenwolf GC, Mansour SL. Mouse FGF15 is the ortholog of human and chick FGF19, but is not uniquely required for otic induction. Dev Biol. 2004;269:264-75.
13. Morón-Ros S, Uriarte I, Berasain C, et al. FGF15/19 is required for adipose tissue plasticity in response to thermogenic adaptations. Mol Metab. 2021;43:101113.
14. Xiao J, Hou Y, Luo X, et al. Clostridium scindens protects against vancomycin-induced cholestasis and liver fibrosis by activating intestinal FXR-FGF15/19 signaling. Adv Sci. 2025;12:e2406445.
15. Lin BC, Wang M, Blackmore C, Desnoyers LR. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem. 2007;282:27277-84.
16. Benoit B, Jalabert A, Meugnier E, et al. Pregnane X receptor deletion induces a lean phenotype in chow-fed mice through a liver-ileum-muscle axis involving 6α-hydroxylated bile acids and Fgf15. Mol Metab. 2026;113:102442.
17. Kim YC, Seok S, Zhang Y, et al. Intestinal FGF15/19 physiologically repress hepatic lipogenesis in the late fed-state by activating SHP and DNMT3A. Nat Commun. 2020;11:5969.
18. Bouju A, Nusse R, Wu PV. A primer on the pleiotropic endocrine fibroblast growth factor FGF19/FGF15. Differentiation. 2024;140:100816.
19. Chaudhari SN, Chen Y, Ferraz-Bannitz R, et al. Alterations in intestinal bile acid transport provide a therapeutic target in patients with post-bariatric hypoglycaemia. Nat Metab. 2025;7:792-807.
20. Potthoff MJ, Boney-Montoya J, Choi M, et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metab. 2011;13:729-38.
21. Zangerolamo L, Carvalho M, Solon C, et al. Central FGF19 signaling enhances energy homeostasis and adipose tissue thermogenesis through sympathetic activation in obese mice. Am J Physiol Endocrinol Metab. 2025;328:E524-42.
22. Aaldijk AS, Verzijl CRC, Hovingh MV, et al. Adult-onset deficiency of β-klotho in the liver reveals a novel role in lipid homeostasis. Mol Metab. 2026;113:102443.
23. Luo Y, Yang C, Ye M, et al. Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations. Cancer Metab. 2013;1:21.
24. Fu T, Choi SE, Kim DH, et al. Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor β-Klotho. Proc Natl Acad Sci U S A. 2012;109:16137-42.
25. Wan ZY, Tian JS, Tan HW, et al. Mechanistic target of rapamycin complex 1 is an essential mediator of metabolic and mitogenic effects of fibroblast growth factor 19 in hepatoma cells. Hepatology. 2016;64:1289-301.
26. Alvarez-Sola G, Uriarte I, Latasa MU, et al. Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice. Cell Death Dis. 2017;8:e3083.
27. Mohammed TA, Zalzala MH. Farnesoid X receptor-mediated bile acids regulation in cholestasis. Indian J Clin Biochem. 2026;41:181-7.
28. Yu Cai Lim M, Kiat Ho H. Pharmacological modulation of cholesterol 7α-hydroxylase (CYP7A1) as a therapeutic strategy for hypercholesterolemia. Biochem Pharmacol. 2024;220:115985.
29. Zhou Z, Xu D, Huang L, Cui Y, Chen H, Tang J. Farnesoid X receptor regulated sepsis-induced abnormal bile acid metabolism via the fibroblast growth factor 15/fibroblast growth factor receptor 4 pathway. Immun Inflamm Dis. 2025;13:e70155.
30. Cheng K, Metry M, Felton J, et al. Diminished gallbladder filling, increased fecal bile acids, and promotion of colon epithelial cell proliferation and neoplasia in fibroblast growth factor 15-deficient mice. Oncotarget. 2018;9:25572-85.
31. Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011;331:1621-4.
32. Wahlström A, Aydin Ö, Olsson LM, et al. Alterations in bile acid kinetics after bariatric surgery in patients with obesity with or without type 2 diabetes. EBioMedicine. 2024;106:105265.
33. Chow MD, Otersen K, Wassef A, et al. Effects of intestine-specific deletion of FGF15 on the development of fatty liver disease with vertical sleeve gastrectomy. Hepatol Commun. 2024;8:e0444.
34. Gadaleta RM, Moschetta A. Metabolic messengers: fibroblast growth factor 15/19. Nat Metab. 2019;1:588-94.
35. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52:1836-46.
36. Tarantino G, Citro V. Liver-spleen axis: deciphering a crucial crosstalk in non-alcoholic fatty liver disease progression and therapeutic implications. World J Gastroenterol. 2026;32:119467.
38. Liu WY, Xie DM, Zhu GQ, et al. Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target. Expert Opin Ther Targets. 2015;19:675-85.
39. Antonellis PJ, Droz BA, Cosgrove R, et al. The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis. Mol Metab. 2019;30:131-9.
40. Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology. 2002;143:1741-7.
41. Miura S, Mitsuhashi N, Shimizu H, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer. 2012;12:56.
42. Li X, Lu W, Kharitonenkov A, Luo Y. Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases. J Intern Med. 2024;295:292-312.
43. Guo C, Zhou N, Lu Y, et al. FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1. Biomed Pharmacother. 2024;170:115955.
44. Cui G, Martin RC, Jin H, et al. Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver. J Exp Clin Cancer Res. 2018;37:136.
45. Patton ME, Kelekar S, Taylor LJ, et al. Sex differences in bile acid homeostasis and excretion underlie the disparity in liver cancer incidence between males and females. Elife. 2025;13:RP96783.
46. Baars A, Oosting A, Lohuis M, et al. Sex differences in lipid metabolism are affected by presence of the gut microbiota. Sci Rep. 2018;8:13426.
47. Seidemann L, Lippold CP, Rohm CM, et al. Sex hormones differently regulate lipid metabolism genes in primary human hepatocytes. BMC Endocr Disord. 2024;24:135.
48. Jiang J, Fan M, Yuan W, et al. Hepatic and intestinal tissue-specific Fxr deficiency alters bile acid homeostasis in female mice. Am J Physiol Gastrointest Liver Physiol. 2025;328:G774-90.
49. Henry ZR, Armstrong L, Maliha S, et al. Deletion of hepatic FXR leads to more severe MASH development in female mice. Hepatol Commun. 2025;9:e0693.
50. Duan X, Nie Y, Xie X, et al. Sex differences and testosterone interfere with the structure of the gut microbiota through the bile acid signaling pathway. Front Microbiol. 2024;15:1421608.
51. Golonka RM, Yeoh BS, Saha P, et al. Sex dimorphic effects of bile acid metabolism in liver cancer in mice. Cell Mol Gastroenterol Hepatol. 2024;17:719-35.
52. Dai M, Shi H, Basaly V, Meadows V, Kong B, Guo GL. Persistent activation of growth hormone contributes to sexual dimorphic expression of hepatic drug metabolizing enzymes in Fgf15 transgenic mice. Drug Metab Dispos. 2026;54:100368.
53. Yan F, Yang C, Huang S, et al. The role of β-Klotho in FGF signaling: from molecular insights to therapeutic innovations. Am J Physiol Endocrinol Metab. 2026;331:E253-71.
54. Bozadjieva-Kramer N, McMahon G, Li Z, et al. Gut-derived FGF15 modulates lean mass, bone, and bile acid responses to weight loss. Diabetes. 2026;75:938-50.
55. Costa DN, Santosa S, Jensen MD. Sex differences in the metabolism of glucose and fatty acids by adipose tissue and skeletal muscle in humans. Physiol Rev. 2025;105:897-934.
56. Kataki C. Sexual dimorphisms in endocrinopathies: their impact on the evolution of metabolic diseases. Mol Cell Endocrinol. 2025;601:112521.
57. Zhang J, Li H, Bai N, et al. Decrease of FGF19 contributes to the increase of fasting glucose in human in an insulin-independent manner. J Endocrinol Invest. 2019;42:1019-27.
58. Bozadjieva-Kramer N, Shin JH, Li Z, et al. Intestinal FGF15 regulates bile acid and cholesterol metabolism but not glucose and energy balance. JCI Insight. 2024;9:e174164.
59. Aaldijk AS, Verzijl CRC, Jonker JW, Struik D. Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho. Front Endocrinol. 2023;14:1150222.
60. Miller KC, Geyer B, Alexopoulos AS, Moylan CA, Pagidipati N. Disparities in metabolic dysfunction-associated steatotic liver disease prevalence, diagnosis, treatment, and outcomes: a narrative review. Dig Dis Sci. 2025;70:154-67.
61. Taylor LC, Arthur G, de Carvalho Cruz M, Stec DE, Badmus OO. Contribution of sex differences to the development of cardiovascular disease in metabolic-associated steatotic liver disease (MASLD). Int J Transl Med. 2024;4:782-809.
62. Penmetsa R, Kapil S, VanWagner LB. Sex and gender differences in metabolic dysfunction-associated liver disease. Indian J Gastroenterol. 2026;45:192-201.
63. Ábel T, Benczúr B, Csobod ÉC. Sex differences in pathogenesis and treatment of dyslipidemia in patients with type 2 diabetes and steatotic liver disease. Front Med. 2024;11:1458025.
64. Zeng Z, Li H, Yang W, et al. Probiotic VSL#3 alleviates intrahepatic cholestasis of pregnancy by upregulating farnesoid X receptor-fibroblast growth factor 15 through regulation of the gut microbiota. J Reprod Immunol. 2025;172:104653.
65. Nguyen QT, Yoshimura K, Takahashi K, et al. Sex disparities in primary biliary cholangitis: insights from a Japanese multicentre cohort. Med Mol Morphol. 2026;Epub ahead of print.
66. Wu YH, Chiu YL, Lin JC, Chen HW. New insights into sex differences in primary biliary cholangitis. Gender difference in primary biliary cholangitis. J Pak Med Assoc. 2022;72:896-900.
67. Xu J, Sun P, Zhu W, Liu X, Ma L. FGF19 in solid tumors: molecular mechanisms, metabolic reprogramming, and emerging therapeutic opportunities. Theranostics. 2026;16:345-97.
68. Matz-Soja M, Berg T, Kietzmann T. Sex-related variations in liver homeostasis and disease: From zonation dynamics to clinical implications. J Hepatol. 2026;84:181-93.
69. Xu ZQ, Luo SQ, Wu ZJ, Liao R. Current status and perspectives of molecular mechanisms of gender difference in hepatocellular carcinoma: the tip of the iceberg? Biosci Trends 2025;19:266-80.
70. Barjesteh F, Heidari-Kalvani N, Alipourfard I, Najafi M, Bahreini E. Testosterone, β-estradiol, and hepatocellular carcinoma: stimulation or inhibition? A comparative effect analysis on cell cycle, apoptosis, and Wnt signaling of HepG2 cells. Naunyn Schmiedebergs Arch Pharmacol. 2024;397:6121-33.
71. Su L, Luo H, Yan Y, et al. Exploiting gender-based biomarkers and drug targets: advancing personalized therapeutic strategies in hepatocellular carcinoma. Front Pharmacol. 2024;15:1433540.
72. Ovadia C, Perdones-Montero A, Spagou K, et al. Enhanced microbial bile acid deconjugation and impaired ileal uptake in pregnancy repress intestinal regulation of bile acid synthesis. Hepatology. 2019;70:276-93.
73. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2:217-25.
74. Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem. 2007;282:26687-95.
75. Xie M, Lin Z, Ji X, et al. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. J Hepatol. 2023;79:109-25.
76. Ding L, Yang L, Wang Z, Huang W. Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin B. 2015;5:135-44.
77. Wei Y, Yang L, Tang C, et al. Lenvatinib inhibits cholangiocarcinoma progression by targeting the FGF19/PI3K/AKT signaling pathway. Apoptosis. 2025;30:185-96.
78. Zou Y, Zheng S, Xie X, et al. N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun. 2022;13:2672.
79. Carvalho MB, Jorge GMCP, Zanardo LW, et al. The role of FGF19 in metabolic regulation: insights from preclinical models to clinical trials. Am J Physiol Endocrinol Metab. 2024;327:E279-89.
80. Rinella ME, Lieu HD, Kowdley KV, et al. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology. 2024;79:674-89.
81. Harrison SA, Rinella ME, Abdelmalek MF, et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2018;391:1174-85.
82. Hirschfield GM, Chazouillères O, Drenth JP, et al. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial. J Hepatol. 2019;70:483-93.
83. Hasan MN, Wang H, Luo W, et al. A Gly-β-muricholic acid and FGF15 combination therapy synergistically reduces “humanized” bile acid pool toxicity in cholestasis mice. J Lipid Res. 2025;66:100936.
84. Harrison SA, Abdelmalek MF, Neff G, et al. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2022;7:603-16.
85. Zhou M, Learned RM, Rossi SJ, DePaoli AM, Tian H, Ling L. Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice. Hepatol Commun. 2017;1:1024-42.
86. Shi H, Stofan M, Kong B, et al. Fibroblast growth factor 15 overexpression and combined peroxisome proliferator-activated receptor α activation attenuates metabolic dysfunction-associated steatohepatitis progression in mice. Drug Metab Dispos. 2025;53:100128.
87. Lopez-Pascual A, Russo-Cabrera JS, Ardaiz N, et al. Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD). Clin Sci. 2024;138:1265-84.
88. Chan SL, Schuler M, Kang YK, et al. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. J Exp Clin Cancer Res. 2022;41:189.
89. Schmidt B, Wei L, DePeralta DK, et al. Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition. Int J Cancer. 2016;138:1494-505.
90. Kim RD, Sarker D, Meyer T, et al. First-in-Human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov. 2019;9:1696-707.
91. Harding JJ, Jungels C, Machiels JP, et al. First-in-Human study of INCB062079, a fibroblast growth factor receptor 4 inhibitor, in patients with advanced solid tumors. Target Oncol. 2023;18:181-93.
92. Macarulla T, Moreno V, Chen LT, et al. Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC). J Clin Oncol. 2021;39:4090.
93. Chen XP, Yen CJ, Huang P, et al. 983P Updated safety and efficacy of ABSK-011 in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a phase I study. Ann Oncol. 2024;35:S671.
94. Cheng Q, Zhang Y, Wang J, et al. 149MO Irpagratinib (ABSK-011) plus atezolizumab in first-line (1L) and immune checkpoint inhibitors (ICIs) treated advanced hepatocellular carcinoma (HCC) with FGF19 overexpression (+): Updated results of the phase II ABSK-011-201 study. Ann Oncol. 2025;36:S63.
95. Huang F, Shi X, Hu M, et al. Blocking of FGFR4 signaling by F30 inhibits hepatocellular carcinoma cell proliferation through HMOX1-dependent ferroptosis pathway. Eur J Pharmacol. 2024;970:176493.
96. Zhou M, Zhu S, Xu C, Liu B, Shen J. A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma. Invest New Drugs. 2023;41:162-7.
97. Xie H, Alem Glison DM, Kim RD. FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential. Expert Opin Investig Drugs. 2022;31:393-400.
98. Goyal L, Al-Rajabi R, Sahin IH, et al. 288eTiP A multicenter, open-label, first-in-human study of TYRA-430 in advanced hepatocellular carcinoma and other solid tumors with activating FGF/FGFR pathway aberrations (SURF431). Ann Oncol. 2025;36:S300.
99. Liu H, Zheng S, Hou X, et al. Novel Abs targeting the N-terminus of fibroblast growth factor 19 inhibit hepatocellular carcinoma growth without bile-acid-related side-effects. Cancer Sci. 2020;111:1750-60.
